Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: Final results of a randomized trial of fasudil versus nimodipine

Neurologia Medico-Chirurgica

Volumn 51, Issue 10, 2011, Pages 679-683

  Zhao, Jizong ^a   Zhou, Dingbiao ^b   Guo, Jing ^c   Ren, Zuyuan ^d   Zhou, Liangfu ^e   Wang, Shuo ^a   Zhang, Yan ^a   Xu, Bainan ^b   Zhao, Kuiming ^c   Wang, Renzhi ^d   Mao, Ying ^e   Xu, Bin ^e   Zhang, Xiaolin ^f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

^f Asahi Kasei Corporation Beijing Office   (China)

Author keywords

Cerebral vasospasm; Fasudil; Nimodipine; Rho kinase inhibitor; Subarachnoid hemorrhage

Indexed keywords

FASUDIL; NIMODIPINE;

ADULT; ARTICLE; BRAIN ISCHEMIA; BRAIN VASOSPASM; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HOT FLUSH; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADULT; AGED; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NIMODIPINE; SUBARACHNOID HEMORRHAGE; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL; YOUNG ADULT;

EID: 80054934973     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.51.679     Document Type: Article

References (23)

1. Arai M, Sasaki Y, Nozaki R: Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol 46: 1487-1490, 1993
2. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H: Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 241: 1033-1040, 1987
3. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, Kassell NF, Lee KS: Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery 53: 123-135, 2003
4. Feske SK, Sorond FA, Henderson GV, Seto M, Hitomi A, Kawasaki K, Sasaki Y, Asano T, Liao JK: Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 1257: 89-93, 2009
5. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A: Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res 93: 767-775, 2003
6. Hitomi A, Satoh S, Ikegaki I, Suzuki Y, Shibuya M, Asano T: Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci 67: 1929-1939, 2000
7. Kawasaki K, Yano K, Sasaki K, Tawara S, Ikegaki I, Satoh S, Ohtsuka Y, Yoshino Y, Kuriyama H, Asano T, Seto M: Correspondence between neurological deficit, cerebral infarct size, and Rho-kinase activity in a rat cerebral thrombosis model. JMol Neurosci 39: 59-68, 2009
8. Osuka K, Suzuki Y, Tanazawa T, Hattori K, Yamamoto N, Takayasu M, Shibuya M, Yoshida J: Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 140: 943-951, 1998
9. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, Liao JK: Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36: 2251-2257, 2005
10. Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87: 195-200, 2000
11. Satoh S, Hitomi A, Ikegaki I, Kawasaki K, Nakazono O, Iwasaki M, Mohri M, Asano T: Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rhokinase inhibitors against ischemic brain damage. Brain Res Bull 81: 191-195, 2010
12. Satoh S, Kobayashi T, Hitomi A, Ikegami I, Suzuki Y, Shibuya M, Yoshida J, Asano T: Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 80: 41-48, 1999
13. Satoh S, Toshima Y, Hitomi A, Ikegami I, Seto M, Asano T: Wide therapeutic time window for Rhokinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 1193: 102-108, 2008
14. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, Shimokawa H: Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455: 169-174, 2002
15. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E: Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238: 31-39, 2005
16. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, Nakashima M: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 76: 571-577, 1992
17. Shimokawa H, Takeshita A: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005
18. Suzuki Y, Satoh S, Kimura M, Oyama H, Asano T, Shibuya M, Sugita K: Effects of vasopressin and oxytocin on canine cerebral circulation in vivo. J Neurosurg 77: 424-431, 1992
19. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K: A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 68: 126-132, 2007
20. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K: Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: Sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48: 241-248, 2008
21. Takizawa T, Tada T, Kitazawa K, Tanaka Y, Hongo K, Kameko M, Uemura K: Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurol Res 23: 724-730, 2001
22. Yano K, Kawasaki K, Hattori T, Tawara S, Toshima Y, Ikegaki I, Sasaki Y, Satoh S, Asano T, Seto M: Demonstration of elevation and localization of Rhokinase activity in the brain of a rat model of cerebral infarction. Eur J Pharmacol 594: 77-83, 2008
23. Zhao J, Zhou D, Guo J, Ren Z, Zhou L, Wang S, Xu B, Wang R: Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 46: 421-428, 2006